Amy | Sales manager

Phone:+86 19142414382(whatsapp)

Email:shengzhikai3@shengzhikai.com

Address: 903, block B, Fortune Plaza, Luyang District, Hefei City, Anhui Province

Linaclotide is a guanylate cyclase-C receptor agonist (GCCA) that has both visceral analgesic effects and endocrine active GC-C activation resulting in increased intracellular and extracellular cGMP concentrations. Extracellular cGMP can reduce the activity of painful nerve fibers and alleviate visceral pain in model animals. Intracellular cGMP can increase the secretion of chloride and bicarbonate in the small intestine by activating CFTR (cystic fibrosis transmembrane conduction regulatory factor), and ultimately lead to increased secretion of small intestinal fluid and rapid small intestinal transport.

Linaclotide is a peptide agonist of the guanylate cyclase 2C.
This compound reduces the activation of colonic sensory neurons, reducing pain; and activates colonic motor neurons, which increases smooth muscle contraction and thus promotes bowel movements.
It was approved by the FDA in August 2012 for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome (IBS-C) in adults.
Linaclotide is an administered, peptide agonist of guanylate cyclase 2C for the treatment of irritable bowel syndrome. Chemically, it is a heterodetic cyclic peptide and consists of fourteen amino acids. 
Linaclotide is used to treat certain types of bowel problems (irritable bowel syndrome with constipation, chronic idiopathic constipation). It works by increasing fluid in your intestines and helping speed up movement of food through the gut. Linaclotide may improve stool texture and lessen symptoms such as bloating, abdominal pain/discomfort, straining, and feelings of incomplete bowel movements.